Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $7.3333.

A number of analysts have issued reports on WHWK shares. Oppenheimer reissued an “outperform” rating and issued a $7.00 price target on shares of Whitehawk Therapeutics in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Wall Street Zen downgraded Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Citizens Jmp assumed coverage on Whitehawk Therapeutics in a report on Thursday, April 16th. They set a “market outperform” rating and a $8.00 price objective for the company. Finally, Citigroup started coverage on Whitehawk Therapeutics in a report on Thursday, April 16th. They set an “outperform” rating for the company.

Whitehawk Therapeutics Trading Up 1.4%

Shares of NASDAQ:WHWK opened at $4.40 on Friday. The stock’s 50-day moving average price is $4.06 and its two-hundred day moving average price is $3.26. Whitehawk Therapeutics has a 12-month low of $1.57 and a 12-month high of $5.49. The firm has a market cap of $217.58 million, a price-to-earnings ratio of -2.62 and a beta of 0.77.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. As a group, research analysts forecast that Whitehawk Therapeutics will post -1.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO David James Lennon sold 14,500 shares of Whitehawk Therapeutics stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $3.38, for a total value of $49,010.00. Following the transaction, the chief executive officer directly owned 518,622 shares of the company’s stock, valued at $1,752,942.36. The trade was a 2.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $3.64, for a total value of $336,554.40. Following the completion of the transaction, the insider directly owned 397,106 shares in the company, valued at $1,445,465.84. This represents a 18.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 695,830 shares of company stock worth $2,553,026 over the last three months. 49.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Whitehawk Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of WHWK. Vanguard Group Inc. acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $2,552,000. Peapod Lane Capital LLC acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $577,000. Dimensional Fund Advisors LP acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $84,000. Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $5,414,000. Finally, Suvretta Capital Management LLC acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $7,030,000. 52.08% of the stock is owned by institutional investors and hedge funds.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.